Although a variety of drugs and therapeutic approaches targeting FXR agonists, GLP-1 receptor agonists, or PPAR agonists are implicated in treatment of NASH, whether and how these treatments affect SAA levels remains to be further explored. The gene discussed is SAA2; the disease is metabolic dysfunction-associated steatohepatitis.